Clinical Trials

Breast Neoplasms, Breast Neoplasms, Male

NCT06760637 2026-03-02

FourLight-3

Phase 3 Recruiting

1,020 enrolled

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT06905301 2026-02-20

IMPULSE

Recruiting

240 enrolled

BreastGastrointestinalGynecologic

Breast Neoplasms

NCT05238922 2026-02-10

Study of INCB123667 in Subjects With Advanced Solid Tumors

Phase 1 Recruiting

604 enrolled

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Digestive System Neoplasms

NCT06797531 2026-02-04

NISLEESA

Recruiting

177 enrolled

Phase 4 Active not recruiting

Breast Neoplasms

NCT05161195 2026-02-02

Roll-over Study to Allow Continued Access to Ribociclib

134 enrolled

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT01872260 2026-01-30

Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer

255 enrolled

Breast Neoplasms

NCT07002177 2026-01-07

A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

Phase 1/2 Recruiting

196 enrolled

Breast Neoplasms

NCT06726148 2026-01-06

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Phase 1/2 Recruiting

280 enrolled

Breast Neoplasms

NCT04943497 2025-12-09

PROSPERITY

2,424 enrolled

Breast Neoplasms

NCT05038631 2025-12-02

Managed Access Programs for LEE011, Ribociclib

Available

Breast Neoplasms

NCT06495164 2025-11-25

A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer

Active not recruiting

1 enrolled

Breast Neoplasms

NCT05867251 2025-11-19

Study of AVZO-021 in Patients With Advanced Solid Tumors

Phase 1/2 Recruiting

430 enrolled

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03671330 2025-10-31

Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.

327 enrolled

Breast Neoplasms

NCT06239467 2025-09-09

PIKture-01

Phase 1 Recruiting

200 enrolled

Breast Neoplasms

NCT05870579 2025-08-21

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

Phase 1 Recruiting

48 enrolled

Breast Neoplasms

NCT07072013 2025-07-18

IRINA

1,937 enrolled

Breast Neoplasms

NCT05384119 2025-02-21

Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer

Phase 1 Terminated

6 enrolled

Breast Neoplasms

NCT06075758 2025-01-14

A Study of Ribociclib in Combination With Hormonal Therapy in HR+/HER2- Advanced or Metastatic Breast Cancer

Recruiting

550 enrolled

Breast Neoplasms

NCT03839823 2024-10-09

RIGHT Choice

222 enrolled 17 charts

Breast Neoplasms

NCT03439046 2024-08-01

BioItaLEE

287 enrolled

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT02422615 2023-11-30

MONALEESA-3

726 enrolled 17 charts 1 FDA

BreastEndocrine

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site, Multiple Endocrine Neoplasia Type 1

NCT02941926 2023-10-24

COMPLEEMENT-1

3,246 enrolled 11 charts

Breast Neoplasms

NCT03462251 2023-01-19

RIBBIT

41 enrolled

Breast Neoplasms

NCT05569187 2022-11-08

Ribociclib in Combination With Non-steroidal Aromatase Inhibitors in Patients With Advanced Breast Cancer

76 enrolled

Breast Neoplasms

NCT05153135 2021-12-21

Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 Inhibitors

4,320 enrolled

Breast Neoplasms

NCT03078751 2021-10-11

EarLEE-1

54 enrolled 9 charts

Breast Neoplasms

NCT03096847 2021-10-11

Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer

502 enrolled 20 charts

Breast Neoplasms, Osteitis Deformans

NCT01857193 2021-04-13

Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer

Phase 1 Completed

132 enrolled

Breast Neoplasms

NCT02154776 2020-12-19

LeeBLet

Phase 1 Completed

13 enrolled

Breast Neoplasms

NCT02088684 2020-12-17

Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer

Phase 1 Completed

70 enrolled

Breast Neoplasms

NCT03050398 2020-05-28

A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib

Phase 3 Terminated

8 enrolled 4 charts

BreastEndocrine

Breast Neoplasms, Multiple Endocrine Neoplasia Type 1

NCT02187783 2019-07-18

SIGNATURE

BreastGynecologicLymphoidOther hematologic neoplasmOther solid neoplasmThoracic

106 enrolled 16 charts

Breast Neoplasms, Leukemia, Lymphoma, Mesothelioma, Neoplasms, Ovarian Neoplasms, Hematologic Neoplasms

NCT01919229 2016-01-01

MONALEESA-1

Phase 2 Terminated

14 enrolled 7 charts